| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/06/2006 | US7056926 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis |
| 06/06/2006 | US7056922 Acylamino cyclopropane derivatives |
| 06/06/2006 | US7056918 Benzimidazole anti-inflammatory compounds |
| 06/06/2006 | US7056914 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 06/06/2006 | US7056910 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
| 06/06/2006 | US7056909 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 06/06/2006 | US7056903 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists |
| 06/06/2006 | US7056902 4-dedimethylamino tetracycline compounds |
| 06/06/2006 | US7056887 Treatment of acute coronary syndrome with GLP-1 |
| 06/06/2006 | US7056885 Fibroblast growth factor and nucleic acids encoding same |
| 06/06/2006 | US7056884 Reduced FK228 and use thereof |
| 06/06/2006 | US7056735 Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) |
| 06/06/2006 | US7056730 Expression of heterologous genes from an IRES translational cassette in retroviral vectors |
| 06/06/2006 | US7056711 Attenuation of fibroblast proliferation |
| 06/06/2006 | US7056704 RNA interference mediating small RNA molecules |
| 06/06/2006 | US7056701 Hormone and albumin fusion protein |
| 06/06/2006 | US7056529 Vesicle comprises ATP and phospholipid; fusion proteins |
| 06/06/2006 | US7056516 Comprises nucleotide sequences coding caspase 8 inhibitory protein for use in the treatment of alzheimer's, parkinson's, arthritic, septic, cardiovascular, inflammatory, osteoporotic and ischemic reperfusion injuries/disorders |
| 06/06/2006 | US7056514 Partial peptide mimetics and methods |
| 06/06/2006 | US7056512 controlling and increasing muscle growth, especially in farm animals for slaughter, by administering an immunogenically effective amount ofa modified GDF-8 polypeptide |
| 06/06/2006 | US7056509 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents |
| 06/06/2006 | CA2457852C Multivesicular emulsion topical delivery systems |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2166800C 4-substituted piperidine derivatives useful as neurokinin antagonists |
| 06/06/2006 | CA2158973C 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity |
| 06/01/2006 | WO2006058303A2 Modulators of muscarinic receptors |
| 06/01/2006 | WO2006057460A1 Nitrogen-containing fused ring compound and use thereof |
| 06/01/2006 | WO2006057448A1 Arylalkanoic acid derivative |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006057217A1 Dfrp proteins regulating drg proteins and utilization of the same |
| 06/01/2006 | WO2006057154A1 Efficacy enhancing agent for anticancer drug |
| 06/01/2006 | WO2006057152A1 Therapeutic agent for diabetes comprising protease-inhibiting compound |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2006020403A3 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 06/01/2006 | WO2004004656A3 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060116518 Novel phenanthridines |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116505 Glucose and/or fructose transporter naglt1 and its gene |
| 06/01/2006 | US20060116426 Inhibitor for perioperative blood sugar elevation |
| 06/01/2006 | US20060116418 Materials and methods for treating hypercholesterolemia |
| 06/01/2006 | US20060116405 Indol derivatives and their use as 5-ht ligands |
| 06/01/2006 | US20060116394 Fab I inhibitors |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116381 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases |
| 06/01/2006 | US20060116378 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity |
| 06/01/2006 | US20060116364 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer |
| 06/01/2006 | US20060116337 Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors |
| 06/01/2006 | US20060115869 Uses of carbamoyl phosphate synthetas for the diagnosis of inflammatory diseases and sepsis |
| 06/01/2006 | US20060115815 Method and compositions for identifying anti-hiv therapeutic compounds |
| 06/01/2006 | US20060115542 Therapeutic delivery of carbon monoxide |
| 06/01/2006 | US20060115538 Calcium lactate and whey permeate for lowering the triglyceride level |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115376 Irradiation in presence of stabilizer; preventing degradation |
| 06/01/2006 | US20060113968 Novel benzonaphthyridines |
| 06/01/2006 | CA2589439A1 Modulators of muscarinic receptors |
| 06/01/2006 | CA2588558A1 Jnk inhibitors for treatment of cns injury |
| 06/01/2006 | CA2579962A1 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 05/31/2006 | EP1662007A1 Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient |
| 05/31/2006 | EP1661994A1 Therapeutic agent for NGF |
| 05/31/2006 | EP1661909A1 Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food |
| 05/31/2006 | EP1661898A1 Bicyclic piperazine compound and use thereof |
| 05/31/2006 | EP1661897A1 Pyrrolopyrimidinone derivative |
| 05/31/2006 | EP1661896A1 Pyrrolopyrimidinethione derivative |
| 05/31/2006 | EP1661892A1 Condensed ring compound and use thereof |
| 05/31/2006 | EP1661889A1 Chemokine receptor antagonist and medical use thereof |
| 05/31/2006 | EP1661881A2 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 05/31/2006 | EP1661879A1 Diphenyl ether compound, process for producing the same, and use |
| 05/31/2006 | EP1661580A1 Remedy for cartilage-related diseases |
| 05/31/2006 | EP1661578A1 Skin ulcer preventive curative agent containing human recombinant hgf |
| 05/31/2006 | EP1661573A1 Ophthalmic composition |
| 05/31/2006 | EP1661572A1 Novel use of cannabinoid receptor agonist |
| 05/31/2006 | EP1661569A1 Compounds effecting glucokinase |
| 05/31/2006 | EP1661568A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661567A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661563A1 Compound effecting Glucokinase |
| 05/31/2006 | EP1453512B1 Acetylene derivatives having mglur 5 antagonistic activity |
| 05/31/2006 | EP1448181B1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 05/31/2006 | EP1446122B1 Use of flibanserin in the treatment of sexual desire disorders |
| 05/31/2006 | EP1441716B1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions |
| 05/31/2006 | EP1419178B1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 05/31/2006 | EP1401821A4 Novel phenylalkyl diamine and amide analogs |
| 05/31/2006 | EP1392295B1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
| 05/31/2006 | EP1368336B1 Thiophene substituted amine derivatives as glyt-1 inhibitors |
| 05/31/2006 | EP1352061B1 Method for inhibiting the expression of a target gene |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1333845A4 Treatment of t cell disorders |
| 05/31/2006 | EP1318997B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317449B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317444B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1315500A4 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 05/31/2006 | EP1296967B1 Benzothiazolyl ppar-gamma modulators |
| 05/31/2006 | EP1296931B1 Polyamine analogues as cytotoxic agents |
| 05/31/2006 | EP1272223B1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 05/31/2006 | EP1272156B1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials |
| 05/31/2006 | EP1268798B1 Anti-angiogenic properties of vascostatin and fragments or variants thereof |
| 05/31/2006 | EP1263467B1 Paste formulations comprising silica |
| 05/31/2006 | EP1235851B1 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/31/2006 | EP1231270B1 Novel protein and dna thereof |
| 05/31/2006 | EP1165110B1 Antagonists of hmg1 for treating inflammatory conditions |